Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

Journal Article (Journal Article;Review)

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals and the high prevalence of activating PI3K/Akt/mTOR pathway alterations in prostate cancer, inhibitors of this pathway have great potential for clinical benefit. Here, we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer.

Full Text

Duke Authors

Cited Authors

  • Bitting, RL; Armstrong, AJ

Published Date

  • June 2013

Published In

Volume / Issue

  • 20 / 3

Start / End Page

  • R83 - R99

PubMed ID

  • 23456430

Electronic International Standard Serial Number (EISSN)

  • 1479-6821

Digital Object Identifier (DOI)

  • 10.1530/ERC-12-0394


  • eng

Conference Location

  • England